Omapro omacetaxine mepesuccinate regulatory update

FDA's Oncologic Drugs Advisory Committee will meet on Feb. 10 to discuss an NDA from ChemGenex for Omapro omacetaxine mepesuccinate to treat Gleevec-resistant chronic myelogenous leukemia (CML) in adu...